ArticleJournal of cancer research and clinical oncology2025

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan.

Jaekyung Cheon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.